课题基金 / 基金详情

Investigation of a new molecular target-based treatment of caneer-drug resistant pediatric solid tumors

Investigation of a new molecular target-based treatment of caneer-drug resistant pediatric solid tumors
癌症耐药儿童实体瘤新分子靶向治疗的研究
批准号:
15591098
负责人:
KAMIJO Takehiko
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

KAMIJO Takehiko的其他基金

相似基金

相关文献

中文摘要
翻译
神经母细胞瘤(NB)是儿童最常见的交感神经系统实体恶性肿瘤。与许多儿童恶性肿瘤存活率的提高不同,高危肺母细胞瘤仍然是最难治愈的肿瘤之一,尽管进行了密集的多模式治疗,但长期存活率只有30%。为了提高存活率,需要新的治疗方法和对耐药机制的更好理解。神经母细胞瘤研究的一个值得注意的发现是,在340例被检测的NBS中,报告的p53肿瘤抑制基因突变不到2%(TwedleDA等人,癌症资源61:8-13,2001)。P53的细胞质隔离被认为是NB细胞失活的另一种机制,而不是突变。首先使用免疫组织化学技术(Moll UM等人,PNAS92:4407-11,1995)在冷冻的肿瘤样本中报告了隔离,后来通过免疫荧光和细胞分离实验…在NB油系中报告了隔离更多S(莫尔·乌姆等人,MCB 16:1126-37,1996)。然而,DNA损伤刺激前后P53的定位,P53的磷酸化稳定和激活,与P53结合的共识序列在体内外的结合,以及P53下游分子在Nb细胞中的上调仍未确定。因此,我们利用一组细胞系来确定Nb细胞中P53依赖的细胞死亡是否由细胞功能凋亡引起,并进一步研究了P53依赖途径诱导细胞凋亡的分子机制。我们提供了一系列证据表明,依赖于P53的压力,阿霉素(Doxo)给药,导致Nb细胞核中P53的积聚,以及在Doxo敏感和耐药的Nb细胞系中几个丝氨酸残基(丝氨酸15、丝氨酸20和丝氨酸46)的磷酸化。P53下游分子p21Cip1/Waf1的上调和促凋亡的Bcl2家族分子Noxa在线粒体中的积聚仅在对Doxo敏感的NB细胞中观察到。敏感细胞线粒体功能障碍,包括细胞色素c释放和膜电位失调,导致caspase内源性通路激活。然而,P53在细胞核内的积聚和P53的磷酸化是惰性的,可以诱导P53耐药的NB细胞NOXA积聚和线粒体功能障碍。令人惊讶的是,MDM2的过度表达使P53失活,导致线粒体中Noxa的上调被取消,并减少了细胞的凋亡。综上所述,MDM2/P53通路可能通过调控线粒体中的NoxA而在NB细胞中发挥重要作用。较少
英文摘要
Neuroblastoma (NB) is the most common pediatric solid malignant tumor derived from the sympathetic nervous system. Unlike the improvements in survival in many childhood malignancies, high-risk neumblastoma is still one of the most difficult tumors to cure, with only 30% long-term survival despite intensive multi-modal therapy. New treatments and a better understanding of drug resistance mechanisms are required for improvement of the survival rates. A noteworthy finding of neuroblastoma research is that mutations of p53 tumor suppressor have been reported less than 2% of NBs out of 340 tested (Tweddle DA et al., Cancer Res 61 : 8-13, 2001). Instead of mutation, cytoplasmic sequestration of p53 has been proposed as an alternative mechanism of inactivation in NB cells. The sequestration was first reported in frozen tumor samples using immuno-histodremical techniques (Moll UM et al., PNAS 92 : 4407-11, 1995) and later in NB oil lines by immuno-fluorescence and cell fractionation experiment … More s (Moll UM et al., MCB 16 : 1126-37, 1996). However, the p53 localization before and after DNA damage stimulation, p53 stabilization and activation by phosphorylation, binding to the p53-binding consensus sequences in vitro and in vivo, and up-regulation of p53-dowmstream molecules in NB cells have remained to be determined.Therefore, we employed a panel of cell lines to determine whether the p53-dependent cell death in NB cells is caused by apoptotic cellular function, and we further studied the molecular mechanism of apoptosis induced via p53-dependent pathway. We provide lines of evidence that a p53-dependent stress, doxorubicin (Doxo) administration, causes accumulation of p53 in nucleus of NB cells and phosphorylation of several serine residues (serine 15, serine 20, and serine 46) in both Doxo-sensitive and -resistant NB cell lines. Up-regulation of a p53-downstream molecule, p2lCip 1/Waf1 and accumulation of Noxa, a pro-apoptotic Bcl-2 family molecule, in mitochondria are observed in only Doxo-sensitive NB cells. Mitochondrial dysfunction including cytochrome c release and membrane potential dysregulation was caused in the sensitive cells, resulting in the activation of the intrinsic caspase pathway. However, the accumulation in nucleus and phosphorylation of p53 were inert to induce the Noxa accumulation and the mitochondrial dysfunction in p53-resistant NB cells. Surprisingly, inactivation of the p53 by over-expression of MDM2 resulted in the canceling of up-regulation of Noxa in mitochondria and reduced the apoptotic cell death. Taken together, MDM2/p53 pathway seems to play an important role in NB cells by Noxa regulation in mitochondria. Less
期刊论文(38)
专著(0)
科研奖励(0)
会议论文
ST1571 inhibits growth and adhesion of human mast cells in culture.
ST1571 抑制培养物中人类肥大细胞的生长和粘附。
DOI: --
发表时间: 2003
期刊: J Leukoc Biol. 74
影响因子: --
作者: [Takeuchi K, Koike K, Kamijo T, 他10名]
通讯作者: 他10名
DOI: 10.1074/jbc.m300510200
发表时间: 2003-07
期刊: Journal of Biological Chemistry
影响因子: 4.8
作者: [Y. Nakazawa;T. Kamijo;K. Koike;T. Noda]
通讯作者: Y. Nakazawa;T. Kamijo;K. Koike;T. Noda
STI571 inhibits growth and adhesion of human mast cells in culture
STI571 抑制培养物中人类肥大细胞的生长和粘附
DOI: 10.1189/jlb.0602284
发表时间: 2003
期刊: Journal of Leukocyte Biology
影响因子: 5.5
作者: [K. Takeuchi, K. Koike, T. Kamijo, S. Ishida, Y. Nakazawa, Y. Kurokawa, K. Sakashita, T. Kinoshita, Shigeyuki Matsuzawa, M. Shiohara, T. Yamashita, M. Nakajima, A. Komiyama]
通讯作者: A. Komiyama
Successful unrelated cord blood transplantation using a reduced-intensity conditioning regimen in a 6-month-old infant with congenital neutropenia complicated by severe pneumonia.
对一名患有先天性中性粒细胞减少症并发严重肺炎的 6 个月大婴儿,使用降低强度调理方案成功进行无关脐带血移植。
DOI: --
发表时间: 2004
期刊: Int J Hematol. 80(3)
影响因子: --
作者: [Nakazawa Y, Sakashita K, Kinoshita M, Saida K, Shigemura T, Yanagisawa R, Shikama N, Kamijo T, Koike K.]
通讯作者: Koike K.
14
    Development of cancer stem cell-targeted therapy by study of tumor sphere formation mechanism using comprehensive and genetic approach
    Screening of polycomb Bmi1 targets for development of Cancer Stem Cell-targeted therapy for neuroblastoma
    • 批准号:
      21591377
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2009
    • 负责人:
      KAMIJO Takehiko
    • 依托单位:
    Investigation of new molecular target of neuroblastoma therapy: The role of p53 pathway in neuroblastoma cell death
    Analysis of Molecular Mechanism of ARF-dependent apoptotic cell death
    国内基金
    海外基金
    H3K27me3–MEG3–MDM2/p53轴在髓母细胞瘤凋亡逃逸中作用机制的研究
    • 批准号:
      2026JJ81839
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      符星
    • 依托单位:
    假尿苷修饰介导tRNA-Glu剪切产生 tRF-30-87R8WP9N1EWJ调控肝癌中MDM2/p53通路的机制研究
    • 批准号:
      JCZRYB202500445
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
    • 依托单位:
    AKAP5竞争性结合MDM2蛋白以正向调控突变型p53在三阴性乳腺癌免疫逃逸中的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      盛贤能
    • 依托单位:
    FEEF1A1通过MDM2调控p53在急性B淋巴细胞白血病中的作用及机制研究